The life sciences research technology developer has received funding in a series A round co-led by corporate investor ABclonal.
Biotech company ABclonal has co-led a RMB200m ($31m) series A round for China-based life sciences research equipment maker Monad, DealStreetAsia reported on Wednesday, citing a company statement. The round was co-led by investment firm Lucion and also featured venture capital fund Wuxi Capital. Co-founded by Zhuhai Nanshan Investment, Monad provides biological instruments and antibody research…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
